By Vivek K. Mobile: 09920183006 Email:email@example.com
Metropolis Healthcare Limited (“Metropolis” or the “Company”), one of the leading diagnostics companies in India, by revenue, as of March 31, 2018 (Source: Frost & Sullivan), has filed an offer document (“Draft Red Herring Prospectus” or “DRHP”) with the Securities Exchange Board of India (SEBI) thereby proposing (subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations) an Initial Public Offering (IPO) of its Equity Shares.
Under the leadership of Ameera Shah (Managing Director), Metropolis has developed a widespread presence across 18 states in India, as of March 31, 2018, with leadership position in west and south India (Source: Frost & Sullivan). Through its widespread operational network, it offers a comprehensive range of clinical laboratory tests and profiles, which are used for prediction, early detection, diagnostic screening, confirmation and/or monitoring of the disease. It also offers analytical and support services to clinical research organizations for their clinical research projects. During the financial year 2018, it conducted approximately 16.0 million tests from approximately 7.7 million patient visits.
The objects of the Offer are to achieve the benefits of listing the Equity Shares on the Stock Exchanges and for the Offer for Sale. The Company’s Initial Public Offering comprises up to 15,269,684 equity shares of Face Value of Rs. 2 each (the “Equity Shares”) for cash at a Price per Equity Share; consisting of an Offer for Sale of up to 5,017,868 Equity Shares by Dr. Sushil Kanubhai Shah (the “Promoter Selling Shareholder”) and up to 10,251,816 Equity Shares by CA Lotus Investments (the “Investor Selling Shareholder”). The Offer Includes a reservation of up to 300,000 Equity Shares for Subscription by Eligible Employees (The “Employee Reservation Portion”). The Offer less The Employee Reservation Portion is hereinafter referred to as The “Net Offer” and such Net Offer aggregates up to 14,969,684 Equity Shares. Read more